HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dean B Evans Selected Research

letrozole (Femara)

2/2012Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
1/2012Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
12/2011Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
5/2011Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.
11/2010Synergistic activity of letrozole and sorafenib on breast cancer cells.
8/2010Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
3/2009Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
1/2009Increase in response rate by prolonged treatment with neoadjuvant letrozole.
1/2009In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
10/2008Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Dean B Evans Research Topics

Disease

30Breast Neoplasms (Breast Cancer)
02/2012 - 10/2003
25Neoplasms (Cancer)
02/2012 - 10/2003
9Carcinoma (Carcinomatosis)
08/2010 - 04/2007
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/2010 - 07/2008
2Adenocarcinoma
08/2010 - 01/2010
2Neoplasm Metastasis (Metastasis)
02/2010 - 05/2007
2Adrenocortical Carcinoma
01/2010 - 03/2009
2Noninfiltrating Intraductal Carcinoma (DCIS)
03/2008 - 08/2007
1Body Weight (Weight, Body)
02/2012
1Hypogonadism (Hypergonadotropic Hypogonadism)
01/2010
1Adrenal Gland Neoplasms (Adrenal Cancer)
01/2010
1Cushing Syndrome
01/2010
1Endometrial Neoplasms (Endometrial Cancer)
05/2009
1Adenoma (Adenomas)
03/2009
1Ductal Carcinoma
03/2008
1Bone Resorption
10/2006
1Fibrosarcoma
03/2004

Drug/Important Bio-Agent (IBA)

29Estrogens (Estrogen)FDA Link
02/2012 - 10/2003
25Aromatase (CYP19)IBA
05/2011 - 07/2005
21letrozole (Femara)FDA LinkGeneric
02/2012 - 10/2003
11HormonesIBA
02/2012 - 07/2005
8TamoxifenFDA LinkGeneric
02/2012 - 10/2003
8Estradiol (Estrace)FDA LinkGeneric
02/2010 - 03/2008
5Aromatase InhibitorsIBA
03/2009 - 01/2007
4Messenger RNA (mRNA)IBA
08/2010 - 04/2007
4Estrone (Folliculin)FDA Link
02/2010 - 10/2008
3anastrozole (Arimidex)FDA LinkGeneric
10/2008 - 01/2007
2Sirolimus (Rapamycin)FDA Link
01/2012 - 11/2010
2everolimusFDA Link
01/2012 - 07/2005
2Estrogen Receptor alphaIBA
01/2012 - 07/2008
2RNA (Ribonucleic Acid)IBA
12/2011 - 02/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2010 - 06/2009
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
08/2010 - 06/2009
2estrone sulfate (Evex)FDA Link
02/2010 - 10/2008
2EnzymesIBA
02/2010 - 03/2008
2Estrogen Receptor betaIBA
02/2010 - 07/2008
2OxidoreductasesIBA
03/2009 - 03/2008
2Steryl-Sulfatase (Steroid Sulfatase)IBA
02/2009 - 03/2008
2Progesterone Receptors (Progesterone Receptor)IBA
01/2009 - 10/2008
2Tissue Inhibitor of Metalloproteinase-1IBA
06/2008 - 05/2007
2Androstenedione (4 Androstene 3,17 dione)IBA
01/2008 - 07/2005
2AndrogensIBA
04/2007 - 07/2005
2Epidermal Growth Factor Receptor (EGF Receptor)IBA
11/2006 - 07/2006
1Fluorouracil (Carac)FDA LinkGeneric
02/2012
1capecitabine (Xeloda)FDA Link
02/2012
14-hydroxytamoxifenIBA
02/2012
1Thymidine PhosphorylaseIBA
02/2012
1doxifluridineIBA
02/2012
1Hyaluronic Acid (Hyaluronan)IBA
05/2011
1Selective Estrogen Receptor Modulators (SERM)IBA
05/2011
1sorafenib (BAY 43-9006)FDA Link
11/2010
1Protein Kinases (Protein Kinase)IBA
11/2010
1Phosphotransferases (Kinase)IBA
11/2010
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
08/2010
1Adenocarcinoma of lungIBA
08/2010
1CytokinesIBA
08/2010
1human PELP1 proteinIBA
02/2010
1Hydrocortisone (Cortisol)FDA LinkGeneric
01/2010
1Testosterone (Sustanon)FDA Link
01/2010
1Dexamethasone (Maxidex)FDA LinkGeneric
01/2010
1Adrenocorticotropic Hormone (ACTH)FDA Link
01/2010
1GonadotropinsIBA
01/2010
1vatalanib (PTK787)IBA
06/2009
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2009
1Angiogenesis InhibitorsIBA
06/2009
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
05/2009
1Ribosomal Proteins (Ribosomal Protein)IBA
03/2009
1AldosteroneIBA
03/2009
1Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
03/2009
1ForskolinIBA
03/2009
1estrone sulfotransferaseIBA
02/2009
1Biological Markers (Surrogate Marker)IBA
01/2009
1NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA
01/2009
1AntibodiesIBA
01/2009
1Estrogen ReceptorsIBA
07/2008
1SteroidsIBA
03/2008
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
01/2008
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
01/2008
13 (or 17)-beta-hydroxysteroid dehydrogenaseIBA
04/2007
1ERRalpha estrogen-related receptorIBA
04/2007
1zoledronic acid (zoledronate)FDA Link
10/2006
1DiphosphonatesIBA
10/2006

Therapy/Procedure

6Heterologous Transplantation (Xenotransplantation)
02/2012 - 03/2004
3Neoadjuvant Therapy
03/2009 - 02/2008
2Lasers (Laser)
08/2010 - 04/2007
2Mastectomy (Mammectomy)
02/2010 - 01/2009
2Aftercare (After-Treatment)
03/2009 - 10/2007
1Segmental Mastectomy (Lumpectomy)
01/2009
1Adjuvant Chemotherapy
10/2008
1Radiotherapy
01/2005